Trial Profile
A trial to evaluate the safety and efficacy of salvage therapy with sunitinib, docetaxel (Tyxane) and cisplatin followed by maintenance vinorelbine for unresectable/metastatic non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 16 May 2016 New trial record